valproic acid has been researched along with Osteosarcoma in 20 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have examined the effects of the repurposed drugs, bezafibrate, medroxyprogesterone acetate and valproic acid on human osteosarcoma cells, i." | 8.02 | Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells. ( Bunce, CM; Ellington, MA; Johnson, WE; Khanim, FL; MacKay, HL; Sheard, JJ; Snow, MD; Southam, AD, 2021) |
| " The aim of the present study was to investigate the effects of sodium valproate (VPA), a histone deacetylase inhibitor, in combination with hydralazine hydrochloride (Hy), a DNA methylation inhibitor, on the expression of VEGI and its related receptors in human osteosarcoma (OS) cell lines and human microvascular endothelial (HMVE) cells." | 7.91 | Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells. ( Fujihara, Y; Futani, H; Kobayashi, K; Kumanishi, S; Nakasho, K; Nishiura, H; Yamanegi, K; Yoshiya, S, 2019) |
| "In this study, we performed combination treatment of caffeine and valproic acid on osteosarcoma cell lines in vitro and in spontaneous and experimental lung metastasis mouse models of osteosarcoma." | 7.85 | Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice. ( Hayashi, K; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Kiyuna, T; Miwa, S; Murakami, T; Tsuchiya, H; Yamamoto, N, 2017) |
| " We subsequently tested the combination of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, with caffeine on established human osteosarcoma cells in vitro." | 7.85 | Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. ( Dry, SM; Eilber, FC; Hayashi, K; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Kiyuna, T; Li, Y; Miwa, S; Murakami, T; Nelson, SD; Singh, AS; Tsuchiya, H; Yamamoto, N, 2017) |
| "Both valproic acid and caffeine caused concentration-dependent cell death of the osteosarcoma cell lines in vitro." | 7.83 | Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models. ( Hayashi, K; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N, 2016) |
| "We investigated the effects of valproic acid (VPA), a histone deacetylase inhibitor, in combination with hydralazine, a DNA methylation inhibitor, on the expression of cell-surface Fas and MHC-class I-related chain molecules A and B (MICA and B), the ligands of NKG2D which is an activating receptor of NK cells, and on production of their soluble forms in HOS, U-2 OS and SaOS-2 human osteosarcoma cell lines." | 7.78 | Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death. ( Fukunaga, S; Futani, H; Hata, M; Kato-Kogoe, N; Kobayashi, K; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K, 2012) |
| "Valproic acid, a histone deacetylase inhibitor, increases the expression of cell surface MHC class I-related chain molecules (MICs) A and B (MICA and B) in osteosarcoma cells and decreases their secretion of soluble MICA and MICB, which are produced by the proteolytic cleavage of cell surface MICs." | 7.78 | Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. ( Fukunaga, S; Futani, H; Hata, M; Kobayashi, K; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K, 2012) |
| " Here, we demonstrated that VPA combined with ZOL revealed the synergistic effect in enhancing antitumor efficacy of γδ T cells against osteosarcoma cells." | 5.48 | Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells ( Li, B; Li, H; Lin, N; Lin, P; Sun, L; Teng, W; Wang, S; Wang, Z; Xue, D; Ye, C; Ye, Z; Zhang, W; Zhou, X, 2018) |
| " We have examined the effects of the repurposed drugs, bezafibrate, medroxyprogesterone acetate and valproic acid on human osteosarcoma cells, i." | 4.02 | Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells. ( Bunce, CM; Ellington, MA; Johnson, WE; Khanim, FL; MacKay, HL; Sheard, JJ; Snow, MD; Southam, AD, 2021) |
| " The aim of the present study was to investigate the effects of sodium valproate (VPA), a histone deacetylase inhibitor, in combination with hydralazine hydrochloride (Hy), a DNA methylation inhibitor, on the expression of VEGI and its related receptors in human osteosarcoma (OS) cell lines and human microvascular endothelial (HMVE) cells." | 3.91 | Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells. ( Fujihara, Y; Futani, H; Kobayashi, K; Kumanishi, S; Nakasho, K; Nishiura, H; Yamanegi, K; Yoshiya, S, 2019) |
| " Here, we investigated the effects of the HDAC inhibitor valproic acid (VPA) and the demethylating agent, 5'azacytidine (DAC) on the stem phenotype of MG63 and Saos2 osteosarcoma cell lines." | 3.88 | HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy. ( Desiderio, V; La Noce, M; Lombardi, A; Mele, L; Paino, F; Papaccio, F; Papaccio, G; Regad, T; Tirino, V, 2018) |
| "In this study, we performed combination treatment of caffeine and valproic acid on osteosarcoma cell lines in vitro and in spontaneous and experimental lung metastasis mouse models of osteosarcoma." | 3.85 | Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice. ( Hayashi, K; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Kiyuna, T; Miwa, S; Murakami, T; Tsuchiya, H; Yamamoto, N, 2017) |
| "This study explored whether valproic acid (VPA, a histone deacetylase inhibitor) could radiosensitize osteosarcoma and primary-culture tumor cells, and determined the mechanism of VPA-induced radiosensitization." | 3.85 | The Effect of VPA on Increasing Radiosensitivity in Osteosarcoma Cells and Primary-Culture Cells from Chemical Carcinogen-Induced Breast Cancer in Rats. ( Cai, Z; Feng, Z; Lim, D; Liu, G; Tian, Y; Tian, Z; Wang, H; Zhang, F, 2017) |
| " We subsequently tested the combination of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, with caffeine on established human osteosarcoma cells in vitro." | 3.85 | Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. ( Dry, SM; Eilber, FC; Hayashi, K; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Kiyuna, T; Li, Y; Miwa, S; Murakami, T; Nelson, SD; Singh, AS; Tsuchiya, H; Yamamoto, N, 2017) |
| "Both valproic acid and caffeine caused concentration-dependent cell death of the osteosarcoma cell lines in vitro." | 3.83 | Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models. ( Hayashi, K; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N, 2016) |
| " We investigated the effects of sodium valproate (VPA) and trichostatin A (TSA), histone deacetylase inhibitors, on the expression of VEGI and its related receptors in human osteosarcoma (OS) cell lines and human microvascular endothelial (HMVE) cells." | 3.81 | Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells. ( Futani, H; Kato-Kogoe, N; Kawabe, M; Kishimoto, H; Nakasho, K; Nishiura, H; Yamada, N; Yamanegi, K; Yoshiya, S, 2015) |
| "We investigated the effects of valproic acid (VPA), a histone deacetylase inhibitor, in combination with hydralazine, a DNA methylation inhibitor, on the expression of cell-surface Fas and MHC-class I-related chain molecules A and B (MICA and B), the ligands of NKG2D which is an activating receptor of NK cells, and on production of their soluble forms in HOS, U-2 OS and SaOS-2 human osteosarcoma cell lines." | 3.78 | Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death. ( Fukunaga, S; Futani, H; Hata, M; Kato-Kogoe, N; Kobayashi, K; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K, 2012) |
| "Valproic acid, a histone deacetylase inhibitor, increases the expression of cell surface MHC class I-related chain molecules (MICs) A and B (MICA and B) in osteosarcoma cells and decreases their secretion of soluble MICA and MICB, which are produced by the proteolytic cleavage of cell surface MICs." | 3.78 | Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. ( Fukunaga, S; Futani, H; Hata, M; Kobayashi, K; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K, 2012) |
| "Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines." | 3.75 | Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. ( Futani, H; Hata, M; Kato-Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamane, J; Yamanegi, K, 2009) |
| " In addition, the chemotherapeutic agent ifosfamide caused a decrease in plasma GPx activity in pediatric osteosarcoma patients." | 3.70 | Plasma glutathione peroxidase and its relationship to renal proximal tubule function. ( Avissar, N; Bhamre, S; Cohen, HJ; Ornt, DB; Salvatierra, O; Scandling, JD; Tham, DM; Tune, BM; Whitin, JC, 1998) |
| "In a sample of archival human osteosarcoma tumor specimens, expression of Hes1 mRNA was inversely correlated with survival (n=16 samples, p=0." | 2.45 | How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. ( Hughes, DP, 2009) |
| " Here, we demonstrated that VPA combined with ZOL revealed the synergistic effect in enhancing antitumor efficacy of γδ T cells against osteosarcoma cells." | 1.48 | Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells ( Li, B; Li, H; Lin, N; Lin, P; Sun, L; Teng, W; Wang, S; Wang, Z; Xue, D; Ye, C; Ye, Z; Zhang, W; Zhou, X, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 15 (75.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sawai, T | 1 |
| Yamanegi, K | 7 |
| Nishiura, H | 3 |
| Futani, H | 7 |
| Tachibana, T | 1 |
| Sheard, JJ | 1 |
| Southam, AD | 1 |
| MacKay, HL | 1 |
| Ellington, MA | 1 |
| Snow, MD | 1 |
| Khanim, FL | 1 |
| Bunce, CM | 1 |
| Johnson, WE | 1 |
| Igarashi, K | 3 |
| Kawaguchi, K | 2 |
| Kiyuna, T | 2 |
| Murakami, T | 2 |
| Yamamoto, N | 3 |
| Hayashi, K | 3 |
| Kimura, H | 3 |
| Miwa, S | 3 |
| Tsuchiya, H | 3 |
| Hoffman, RM | 3 |
| Liu, G | 1 |
| Wang, H | 1 |
| Zhang, F | 1 |
| Tian, Y | 1 |
| Tian, Z | 1 |
| Cai, Z | 1 |
| Lim, D | 1 |
| Feng, Z | 1 |
| Nelson, SD | 1 |
| Dry, SM | 1 |
| Li, Y | 1 |
| Singh, AS | 1 |
| Eilber, FC | 1 |
| Wang, S | 1 |
| Li, H | 1 |
| Ye, C | 1 |
| Lin, P | 1 |
| Li, B | 1 |
| Zhang, W | 1 |
| Sun, L | 1 |
| Wang, Z | 1 |
| Xue, D | 1 |
| Teng, W | 1 |
| Zhou, X | 1 |
| Lin, N | 1 |
| Ye, Z | 1 |
| La Noce, M | 1 |
| Paino, F | 1 |
| Mele, L | 1 |
| Papaccio, G | 1 |
| Regad, T | 1 |
| Lombardi, A | 1 |
| Papaccio, F | 1 |
| Desiderio, V | 1 |
| Tirino, V | 1 |
| Kumanishi, S | 1 |
| Fujihara, Y | 1 |
| Kobayashi, K | 4 |
| Nakasho, K | 6 |
| Yoshiya, S | 2 |
| Wang, CK | 1 |
| Yu, XD | 1 |
| Li, Q | 1 |
| Xie, G | 1 |
| Teng, Y | 1 |
| Kawabe, M | 1 |
| Yamada, N | 5 |
| Kato-Kogoe, N | 4 |
| Kishimoto, H | 1 |
| Takeuchi, A | 1 |
| Yamane, J | 4 |
| Hata, M | 4 |
| Ohyama, H | 4 |
| Okamura, H | 4 |
| Terada, N | 4 |
| Hughes, DP | 1 |
| Wittenburg, LA | 2 |
| Bisson, L | 1 |
| Rose, BJ | 1 |
| Korch, C | 1 |
| Thamm, DH | 2 |
| Blattmann, C | 1 |
| Oertel, S | 1 |
| Ehemann, V | 1 |
| Thiemann, M | 1 |
| Huber, PE | 1 |
| Bischof, M | 1 |
| Witt, O | 1 |
| Deubzer, HE | 1 |
| Kulozik, AE | 1 |
| Debus, J | 1 |
| Weber, KJ | 1 |
| Nishioka, T | 1 |
| Fukunaga, S | 3 |
| Ptitsyn, AA | 1 |
| Whitin, JC | 1 |
| Tham, DM | 1 |
| Bhamre, S | 1 |
| Ornt, DB | 1 |
| Scandling, JD | 1 |
| Tune, BM | 1 |
| Salvatierra, O | 1 |
| Avissar, N | 1 |
| Cohen, HJ | 1 |
1 review available for valproic acid and Osteosarcoma
| Article | Year |
|---|---|
How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize.
Topics: Basic Helix-Loop-Helix Transcription Factors; Bone Development; Bone Neoplasms; Histone Deacetylase | 2009 |
19 other studies available for valproic acid and Osteosarcoma
| Article | Year |
|---|---|
Sodium Valproate Enhances Semaphorin 3A-mediated Anti-angiogenesis and Tumor Growth Inhibition in Human Osteosarcoma Cells.
Topics: Bone Neoplasms; Histone Deacetylase Inhibitors; Humans; Neovascularization, Pathologic; Neuropilin-1 | 2023 |
Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells.
Topics: Bezafibrate; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Repositioni | 2021 |
Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Caffeine; Cell Death; Cell | 2017 |
The Effect of VPA on Increasing Radiosensitivity in Osteosarcoma Cells and Primary-Culture Cells from Chemical Carcinogen-Induced Breast Cancer in Rats.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; Chromosome Aberrations; DNA Breaks, Double-Stranded; DNA | 2017 |
Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines.
Topics: Apoptosis; Caffeine; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Histone Deacetylase Inhib | 2017 |
Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyt | 2018 |
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
Topics: Animals; Azacitidine; Bone Neoplasms; Cell Line, Tumor; DNA Methylation; Heterografts; Histone Deace | 2018 |
Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Topics: Bone Neoplasms; Cell Line; Cell Line, Tumor; Drug Synergism; Endothelial Cells; Enzyme Inhibitors; E | 2019 |
Chloroquine and valproic acid combined treatment in vitro has enhanced cytotoxicity in an osteosarcoma cell line.
Topics: Anticonvulsants; Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, | 2013 |
Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells.
Topics: Cell Line, Tumor; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Histone Deacetylase Inhibito | 2015 |
Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Caffeine; Caspase 3; Caspas | 2016 |
Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death.
Topics: Antibodies; Bone Neoplasms; Cell Death; Cell Proliferation; Down-Regulation; Drug Evaluation, Precli | 2009 |
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; | 2011 |
Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
Topics: Antigens, Nuclear; Apoptosis; Carrier Proteins; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Rep | 2010 |
Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
Topics: Antigens, Surface; Bone Neoplasms; Cell Line, Tumor; Cell Membrane; Combined Modality Therapy; Gene | 2010 |
A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Dogs; Down-Regulation; Endothelin- | 2012 |
Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytotoxicity, Immunologi | 2012 |
Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells.
Topics: Bone Neoplasms; Cell Line, Tumor; Dipeptides; Down-Regulation; Histocompatibility Antigens Class I; | 2012 |
Plasma glutathione peroxidase and its relationship to renal proximal tubule function.
Topics: Adult; Animals; Antibodies; Cephaloglycin; Child; Creatinine; Fanconi Syndrome; Glutathione Peroxida | 1998 |